Clinical Trials (Phase I)

Found 12,783 articles

• First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients

  1/17/2019

  IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the first patient has been treated in the Phase 1 trial evaluating neoepitopes formulated in the Company’s proprietary DPX delivery platform in patients with ovarian cancer.

• Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

  1/17/2019

  The poster (Board J1, Abstract #91) can be found online at Five Prime Therapeutics Scientific Publications.

• Isofol Reports Early Tumor Shrinkage in Patients With Colorectal Cancer in Phase 1/2a Open Label Extension Study with Arfolitixorin

  1/17/2019

  Isofol Medical AB (publ), announced positive results from an open-label extension study for the ISO-CC-005 Phase 1/2a study of arfolitixorin in patients with metastatic colorectal cancer (mCRC)

• Targovax Granted European Patent for Mutant-RAS Neoantigen Platform Lead Products

  1/17/2019

  Extends IP protection of TG01 and TG02 until 06.05.2034

• Ipsen Presents the Results of the First in-Human Study of a Recombinant Fast-Acting Neurotoxin (rBoNT-E) at TOXINS 2019

  1/17/2019

  Safety, tolerability and pharmacodynamics of BoNT-E demonstrated in Phase I study

• ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors

  1/16/2019

  Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors

• AIVITA Biomedical Receives IND Clearance for Phase 1B Melanoma Trial

  1/16/2019

  AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1B clinical trial investigating the Company's ROOT OF CANCER technology in patients with metastatic melanoma.

• Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogic’s Synthetic Biotic™ Medicine in Development as a Potential Treatment for Hyperammonemia

  1/16/2019

  Phase 1 clinical trial to evaluate safety and tolerability of SYNB1020 in healthy volunteers demonstrated safety, clearance and proof of mechanism

• 

  Your Feedback Matters! Topics in 2019

  1/15/2019

  As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.

• CarThera obtains ANSM approval to launch its Phase I-II clinical trial for the SonoCloud-9 device in the treatment of recurrent glioblastoma

  1/15/2019

  CarTher today announces it has secured approval from the French National Agency for Medicines and Health Products Safety (ANSM) to start a Phase I-II clinical trial of its SonoCloud-9 device in the treatment of recurrent glioblastoma.

• Innovent Announces First Patient Dosed in a Phase I Clinical Trial of Anti-CD47 Monoclonal Antibody

  1/15/2019

  Innovent Biologics, Inc. announced that the first patient has been successfully dosed in a phase I clinical trial of anti-CD47 monoclonal antibody (IBI188) for patients with advanced malignancies.

• Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium

  1/14/2019

  Compugen Ltd. today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, will be featured in a trial-in-progress poster at The ASCO-SITC Clinical Immuno-Oncology Symposium, taking place February 28-March 2, 2019, in San Francisco, CA.

• CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial

  1/14/2019

   CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with relapsed or refractory colorectal cancer (CRC) who have been previously treated with standard of care (SOC) therapy.

• Five Prime Therapeutics Announces Two Poster Presentations at the 2019 Gastrointestinal Cancers Symposium

  1/14/2019

  Phase 1 Results from the Phase 1/3 FIGHT Study Evaluating Bemarituzumab and mFOLFOX6 in Advanced Gastric and Gastric Esophageal Junction (GEJ) Cance

• SightGlass Vision Multicenter Trial to Study Novel Eyeglasses to Control Nearsightedness for FDA Approval

  1/10/2019

  SightGlass Vision, Inc., a medical device company developing spectacle lenses to slow the progression of nearsightedness or myopia in children, today announced its ground-breaking, pivotal clinical trial to control nearsightedness in children, CYPRESS, is currently enrolling patients in the U.S. and Canada.

• Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-1287 in Phase 1 Study in Patients with Advanced Solid Tumors

  1/10/2019

  Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced that the first patient has been dosed in a Phase 1 study evaluating the investigational agent TP-1287,

• ChemomAb Doses First Patient in Phase 1b Clinical trial of CM-101 in Patients With Non-Alcoholic Fatty Liver Disease

  1/10/2019

  ChemomAb announced dosing of the first patient in a Phase 1b repeated dose clinical trial with CM-101 in non-alcoholic fatty liver disease (NAFLD) patients.

• Cellular Biomedicine Group Initiates Patient Recruitment for Clinical Trial in B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting Multiple Myeloma (MM)

  1/9/2019

  Cellular Biomedicine Group Inc. today announces the initiation of patient recruitment to support the study of anti-BCMA CAR-T therapy targeting relapsed and refractory Multiple Myeloma in China.

• BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149

  1/9/2019

  BGB149 is the first therapeutic anti-AXL monoclonal antibody to enter clinical development BGB149 is BerGenBio's second novel clinical candidate targeting AXL Phase I study will investigate safety and pharmacokinetics in healthy volunteers   [09-January-2019]   BERGEN, Norway, Jan. 9 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage bioph

• Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor

  1/8/2019

  AVID200 is a rationally designed and highly potent TGF-beta 1 & 3 inhibitor